MX372986B - Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) - Google Patents

Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)

Info

Publication number
MX372986B
MX372986B MX2017003627A MX2017003627A MX372986B MX 372986 B MX372986 B MX 372986B MX 2017003627 A MX2017003627 A MX 2017003627A MX 2017003627 A MX2017003627 A MX 2017003627A MX 372986 B MX372986 B MX 372986B
Authority
MX
Mexico
Prior art keywords
sub
idh
inhibitors
quinolinone
pyrimidine
Prior art date
Application number
MX2017003627A
Other languages
English (en)
Other versions
MX2017003627A (es
Inventor
Ann- Marie Campbell
Anna Ericsson
Jr David R Lancia
Gary Gustafson
Jian Lin
Justin Andrew Caravella
R Bruce Diebold
Susan Ashwell
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2017003627A publication Critical patent/MX2017003627A/es
Publication of MX372986B publication Critical patent/MX372986B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a inhibidores de proteínas de isocitrato deshidrogenasa mutante (mt-IDH) con actividad neomórfica útiles en el tratamiento de trastornos de proliferación celular y cánceres, que poseen la Fórmula: (ver fórmula), donde A, B, W1, W2, W3 y R1-R6 se describen la presente.
MX2017003627A 2014-09-19 2015-09-18 Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) MX372986B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462053010P 2014-09-19 2014-09-19
PCT/US2015/051044 WO2016044781A1 (en) 2014-09-19 2015-09-18 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
MX2017003627A MX2017003627A (es) 2018-01-24
MX372986B true MX372986B (es) 2020-03-31

Family

ID=55525126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003627A MX372986B (es) 2014-09-19 2015-09-18 Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)

Country Status (8)

Country Link
US (4) US9815817B2 (es)
EP (1) EP3194383B1 (es)
JP (1) JP6648116B2 (es)
AU (1) AU2015317321B2 (es)
CA (1) CA2961793C (es)
ES (1) ES2768694T3 (es)
MX (1) MX372986B (es)
WO (1) WO2016044781A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6779867B2 (ja) 2014-06-13 2020-11-04 ユマ セラピューティクス,インコーポレーテッド ピリミジン化合物およびその使用方法
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6648116B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス,インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107216312B (zh) * 2016-03-22 2023-08-01 上海海和药物研究开发股份有限公司 一种具有突变型idh抑制活性的化合物、其制备方法及用途
WO2018095344A1 (en) * 2016-11-24 2018-05-31 Shanghai Meton Pharmaceutical Co., Ltd Isocitrate dehydrogenase (idh) inhibitor
EP3555079A4 (en) * 2016-12-19 2020-08-19 Isocure Biosciences Inc. INHIBITORS OF MUTANT ISOCITRATEHYDROGENASES AND COMPOSITIONS AND METHODS FOR THEREOF
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
CN108558774A (zh) * 2018-04-26 2018-09-21 南京药石科技股份有限公司 一种合成卤代-氨甲基取代嘧啶及其盐的方法
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
CN110499091B (zh) * 2019-08-16 2021-04-27 安徽省优亲科技发展有限公司 一种纳米银-壳聚糖改性聚苯磺酰胺抗菌涂层及其制法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO2004043936A1 (ja) * 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Plk阻害剤
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005095382A1 (ja) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規2環性複素環化合物
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
TWI547493B (zh) * 2011-09-27 2016-09-01 諾華公司 作為突變idh之抑制劑之3-嘧啶-4-基-唑啶-2-酮
CA2859985C (en) 2011-12-21 2020-11-03 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same
UA117451C2 (uk) 2012-01-06 2018-08-10 Аджиос Фармасьютікалз, Інк. Терапевтично активні сполуки і способи їх застосування
EA028122B1 (ru) 2013-03-14 2017-10-31 Новартис Аг 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6648116B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス,インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6901394B2 (ja) 2014-12-22 2021-07-14 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の処置に有用な変異型idh1阻害剤
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US9615817B2 (en) 2015-02-27 2017-04-11 Surgical Innovations Llc Wound closure apparatus and method
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
CN107849059B (zh) 2015-07-27 2020-04-28 伊莱利利公司 7-苯基乙基氨基-4h-嘧啶并[4,5-d][1,3]噁嗪-2-酮化合物及其作为突变体idh1抑制剂的用途
JP6930991B2 (ja) 2016-02-26 2021-09-01 セルジーン コーポレイション 血液学的悪性腫瘍及び固形腫瘍の治療のためのidh2阻害剤
EP3464281B1 (en) 2016-06-06 2020-07-08 Eli Lilly and Company Mutant idh1 inhibitors
AU2017281088B2 (en) 2016-06-22 2021-05-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
EA036112B1 (ru) 2016-12-16 2020-09-29 Эли Лилли Энд Компани 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2

Also Published As

Publication number Publication date
ES2768694T3 (es) 2020-06-23
EP3194383A1 (en) 2017-07-26
US20190263779A1 (en) 2019-08-29
US20160083365A1 (en) 2016-03-24
US9815817B2 (en) 2017-11-14
EP3194383B1 (en) 2019-11-06
US20190210995A1 (en) 2019-07-11
US20180134682A1 (en) 2018-05-17
CA2961793A1 (en) 2016-03-24
US10550099B2 (en) 2020-02-04
JP6648116B2 (ja) 2020-02-14
WO2016044781A1 (en) 2016-03-24
AU2015317321B2 (en) 2020-03-12
CA2961793C (en) 2021-03-16
AU2015317321A1 (en) 2017-05-04
US10280150B2 (en) 2019-05-07
JP2017528492A (ja) 2017-09-28
MX2017003627A (es) 2018-01-24

Similar Documents

Publication Publication Date Title
MX372986B (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
MX372964B (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
ZA202304409B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2017003626A (es) Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12019501261A1 (en) Heterocyclic inhibitors of mct4
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
CL2016002839A1 (es) Derivados de carboxamida
EA201791530A1 (ru) НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза

Legal Events

Date Code Title Description
FG Grant or registration